We might not a get partnership announcement but we won't be getting nothing for a month. the type b minutes confirming just how aligned the fda is are coming early next month. It removes a layer of regulatory uncertainty. Gives us credibility and clarity on the path forward e.g. timeframe, the size of initially approved patient population. The endpoints and so on. This is not just another case of go do another trial. See you in 3 years. squeezes are exciting but over rated imo. I dont trade so for me they just lead to diassappointment on the inevitable pullback. I'll be very happy if momentum is maintained with adult gvhd meeting then followed with strong news on rollout and sales, the next month has potential to be great. then with label/international expansion , and long awaited potential to realise new partnerships . squeeze or not, second half will not just be good for lth, it will be glorious.
MSB Price at posting:
$1.58 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)